Compare HZO & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HZO | KURA |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 749.0M | 841.6M |
| IPO Year | 1998 | 2015 |
| Metric | HZO | KURA |
|---|---|---|
| Price | $36.33 | $10.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $30.00 | $25.56 |
| AVG Volume (30 Days) | 247.5K | ★ 1.6M |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $2,309,288,000.00 | $67,482,000.00 |
| Revenue This Year | $3.67 | $28.28 |
| Revenue Next Year | $4.01 | $106.37 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $21.41 | $5.45 |
| 52 Week High | $38.14 | $12.49 |
| Indicator | HZO | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 56.35 | 45.11 |
| Support Level | $32.36 | $8.53 |
| Resistance Level | $36.19 | $10.97 |
| Average True Range (ATR) | 1.60 | 0.52 |
| MACD | -0.13 | -0.17 |
| Stochastic Oscillator | 84.43 | 8.33 |
MarineMax Inc is a United-States-based company that sells new and used recreational boats under premium brands, and related marine products, like engines, parts, and accessories. The company is also engaged in other businesses, including providing services of repair, maintenance, and storage; managing related boat financing, insurance, and others; offering brokerage sales of boats and yachts; and operating a yacht charter business. The reportable segments of the company are Retail Operations and Product Manufacturing. The Retail Operations segment generates the majority of the company's revenue. The sale of new and used boats accounts for the majority of the company's total revenue. It serves customers across the U.S and international market.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.